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Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD),
often regarded as the hepatic manifestation of the metabolic syndrome, increases
worldwide representing now the prevalent liver disease in western countries. No
pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone
treatment is lifestyle modifications focusing on bodyweight loss, notoriously difficult
to obtain and even more difficult to maintain. Thus, novel therapeutic approaches
are highly demanded. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs)
are approved for the treatment of type 2 diabetes and obesity. They exert their
body weight-lowering effect by reducing satiety and food intake. GLP-1RAs have
also been shown to reduce liver inflammation and fibrosis. Furthermore, glucagon
receptor agonism is being investigated for the treatment of NAFLD due to its appetite
and food intake-reducing effects, as well as its ability to increase lipid oxidation and
thermogenesis. Recent studies suggest that glucagon receptor signaling is disrupted in
NAFLD, indicating that supra-physiological glucagon receptor agonism might represent
a new NAFLD treatment target. The present review provides (1) an overview in the
pathophysiology of NAFLD, including the potential involvement of GLP-1 and glucagon,
(2) an introduction to the currently available GLP-1RAs and (3) outlines the potential
of emerging GLP-1RAs and GLP-1/glucagon receptor co-agonists in the treatment of
NAFLD.
Keywords: glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, glucagon, non-alcoholic fatty liver
disease, non-alcoholic steatohepatitis
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is defined as fat
accumulation in more than 5% of the hepatocytes. NAFLD
can be subdivided according to the level of inflammation
ranging from simple steatosis without inflammation to non-
alcoholic steatohepatitis (NASH), which is often associated with
fibrosis and over time may lead to cirrhosis and end-stage
liver failure. NAFLD also increases the risk of hepatocellular
carcinoma (HCC) (1).
The prevalence of NAFLD is increasing. Nearly 25% of
the population in western countries have NAFLD and up
to 6.5% fulfill the criteria of NASH (2). The increased
prevalence of end-stage liver failure and HCC due to progressive
NAFLD has led NAFLD to become the second most common
indication for liver transplantation, likely configuring the
leading indication for liver transplantation within the next two
decades (3).
NAFLD is considered the “hepatic manifestation” of
metabolic syndrome (4). Indeed, NAFLD is associated with
central visceral adiposity except for a small proportion of lean
patients, in whom genetic predisposition might play a crucial
role in liver steatosis and fibrosis. Most morbidly obese patients
undergoing bariatric surgery have NAFLD, nearly 30% have
NASH, and 10% have advanced liver fibrosis (5). NAFLD is also
closely linked with type 2 diabetes (T2D). In T2D the prevalence
of NAFLD raises up to 70–75%, and the prevalence of NASH and
advanced fibrosis are 65 and 15%, respectively (6). Importantly,
coexisting T2D almost doubles the rate of which NAFLD
progresses to end-stage liver disease and HCC, respectively (7, 8).
A recent meta-analysis comprising nearly 300,000 individuals
showed that patients with NAFLD have an increased risk of
developing T2D compared to controls [hazard ratio (HR) 2.22,
95% CI 1.84–2.60], and that risk of T2D increases across the
stages of NAFLD (9). In addition to T2D, NAFLD is accompanied
and complicated by several other extra-hepatic manifestations.
By stimulating pro-inflammatory and pro-thrombotic factors,
it contributes to the development of several chronic diseases,
including ischemic heart disease, cardiomyopathy, cardiac
arrhythmias and chronic kidney disease. Noteworthy, the leading
cause of mortality in NAFLD is cardiovascular disease (CVD)
(10, 11).
No pharmacological therapies are approved for the
treatment of NAFLD and lifestyle changes focusing on caloric
restriction and weight loss constitute the general treatment
recommendations. Recent trials investigating glucagon-like
peptide-1 (GLP-1) receptor (GLP-1R) agonists (GLP-1RAs)
for the treatment of NAFLD have shown promising results.
Furthermore, GLP-1R/glucagon receptor dual agonists are being
investigated for the treatment of NAFLD (12). In addition to its
effects on glucose metabolism, glucagon is suggested to induce
body weight loss, by increasing satiety and enhancing hepatic
lipid oxidation and whole-body energy expenditure (13). This
review provides (1) insights into the pathogenesis of NAFLD
including the potential involvement of GLP-1 and glucagon, (2)
a critical appraisal of the applicability of GLP-1RAs in NAFLD
treatment, and (3) a review of the evidence for GLP-1/glucagon
receptor co-agonism as a novel approach in the treatment of
NAFLD.
THE PATHOGENESIS OF NON-ALCOHOLIC
FATTY LIVER DISEASE
The first phase of NAFLD is characterized by accumulation of
fat in the liver (hepatic steatosis), which may progressively lead
to NASH (in 5–20% of patients) with or without concomitant
fibrosis. Among the patients who develop NASH, 10–20% will
progress to higher-grade fibrosis and approximately 5% will
develop overt cirrhosis (14). It is arguable whether advanced
fibrosis may regress, whereas steatosis and NASH are both
reversible conditions (15). NAFLD-associated cirrhosis has
traditionally been regarded as the leading risk factor for
the development of HCC. However, HCC may also occur
in a non-cirrhotic liver (16, 17). This suggests that NAFLD
might not necessarily implicate a sequential process to evolve
(Figure 1) (18).
Triglycerides (TG) accumulation is likely one of the first
steps in the pathophysiology of NAFLD as a result of an
impaired free fatty acid (FFA) metabolism in the liver (Figure 2).
Excessive caloric intake increases FFA load to the liver to a
point that the ability of the hepatocytes to oxidize FFA or
re-esterify to TG and secrete very low-density lipoproteins
(VLDL) is overwhelmed. Thus, TG accumulate in forms of lipid
drops (steatosis). Moreover, insulin resistance of the adipose
tissue, associated with overweight/obesity, contributes to the flux
of FFA from adipose tissue to the liver through unrestricted
lipolysis (19). Lastly, increased de novo lipogenesis, i.e., hepatic
FFA synthesis, seems to contribute to lipid deposition (20).
Prolonged accumulation of lipids in hepatocytes is associated
with lipotoxicity, which may initiate inflammation, apoptosis
and ultimately fibrosis (21). The main route of hepatic fat
oxidation is the mitochondrial tricarboxylic acid (TCA) cycle. An
overactive TCA cycle stresses the endoplasmic reticulum, thus
inducing mitochondrial dysfunction and formation of reactive
oxidative species and toxic lipid intermediates, like ceramides
and diacylglycerol (22, 23). Insulin resistant adipose tissue
may also enhance inflammation by lowering release of anti-
inflammatory adipokines such as adiponectin and increasing
release of leptin and pro-inflammatory cytokines like interleukin
6 (IL-6) and tumor necrosis factor-alpha (TNF-α) (24). This
inflammatory milieu may contribute to hepatic insulin resistance
and thus establish a vicious circle. At a molecular level, serine
phosphorylation of insulin receptor substrate-1 (IRS-1) by
inflammatory signals appears to be one of the key aspects that
disrupt insulin-receptor signaling (25).
The gut-derived incretin hormones GLP-1 and glucose-
dependent insulinotropic polypeptide (GIP) are responsible
for the so-called incretin effect (i.e., the potentiation of
glucose-stimulated insulin secretion after meal ingestion) (26).
Additionally, GLP-1 suppresses glucagon release from pancreatic
alpha cells, delays gastric emptying and enhances satiety (27).
While GIP displays similar insulinotropic properties, it has
been shown to act as a bifunctional blood glucose stabilizer
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FIGURE 1 | The NAFLD spectrum and relative probabilities to progress across the stages of liver damage. Aside to a classical development in the natural history of
the disease, alternative routes (dotted lines) directly leading to hepatocellular carcinoma (HCC) from simple steatosis or NASH are possible. Hepatic steatosis and
NASH are both reversible conditions (dashed arrows).
FIGURE 2 | The pathophysiology of NAFLD includes dietary fat contribution, hepatic and adipose tissue insulin resistance, proinflammatory cytokines, lipotoxicity and
oxidative stress. A reduced hepatic glucagon resistance (dashed lines), together with an impaired incretin effect, may be additional mechanisms.
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by stimulating glucagon release in the presence of low plasma
glucose levels. Moreover, GIP receptor activation has reported
contrasting effects on satiety, caloric intake and body weight
(28). It has been suggested that patients with NAFLD have
lower concentrations of biologically active incretin hormones
compared to healthy individuals, which may be a consequence of
an increased degradation by dipeptidyl peptidase 4 (DPP-4) (the
enzyme, which under normal conditions inactivates the incretin
hormones) (29) or a decreased production (30, 31). Conversely, a
series of studies by our group suggest that patients with NAFLD
have normal GLP-1 and GIP plasma levels, even though they
exhibit a reduced incretin effect (32). Whether a reduced incretin
effect (reduced beta cell sensitivity to GIP and/or GLP-1) may
play a role in the pathophysiology of NAFLD warrants further
investigations.
Glucagon is a key hormone in the regulation of overall energy
homeostasis during the fasting state and other energy-demanding
situations. Beyond the stimulation of hepatic glucose production,
it also affects hepatic fat metabolism promoting lipid oxidation
and lowering lipid synthesis. Glucagon decreases food intake and
appetite by central mechanism and by reducing gastric emptying
(33, 34). Furthermore, glucagon may display thermogenic
properties, inducing an increase in energy expenditure through
brown adipose tissue activation (13, 35). It has been hypothesized
that hepatic glucagon resistance might play an important role
in fat accumulation in the liver and vice versa (36). Preclinical
studies in NAFLD have demonstrated that a reduction in G
protein-coupled glucagon receptor (GCGR) signaling results
in an increase of hepatic fat content (37, 38). Moreover, a
recent study from Guzman and colleagues (39) has shown
that, in patients with T2D, treatment with a selective GCGR
antagonist, LY2409021, induces a significant increase in hepatic
lipid content assessed bymagnetic resonance imaging, suggesting
that GCGR activation is required to prevent build-up of fat
in the hepatocytes. It has been hypothesized that a reduction
in hepatic GCGR and signaling molecules affects a feedback
mechanism acting on the pancreatic alpha cells, increasing
glucagon secretion, and this liver-pancreas axis might contribute
to fasting hyperglucagonemia (36). In line with this hypothesis,
results from our group show that individuals with NAFLD
(both normoglycemic individuals and patients with T2D) exhibit
significantly higher fasting plasma glucagon levels compared
to matched controls without NAFLD (28). However, whether
hyperglucagonemia is directly involved in the pathogenesis of
NAFLD or is a consequence of steatosis remains uncertain.
TREATMENT OF NAFLD: APPLICABILITY
OF GLP-1RAs
Potential Modes of Action of GLP-1RAs in
NAFLD
Current NAFLD treatment consists of interventions promoting
bodyweight loss. It has been estimated by studies with 1H-
magnetic resonance spectroscopy that decreasing bodyweight
by 10% via diet combined with physical activity can induce
a reduction in hepatic TG concentration up to nearly 60% in
overweight individuals (40). Bariatric surgery is the most
effective treatment in severely obese patients, inducing
significant improvement in lobular inflammation and a
disappearance of NASH in 50–85% of cases (41). Currently
no pharmacological treatment has proven efficacious, however
numerous drugs targeting key-steps in NAFLD pathogenesis
are under investigation. These compounds can be grouped in
medications targeting (1) metabolic derangements including
excess bodyweight, (2) inflammation and oxidative stress, and (3)
dysregulation of the gut-liver axis (42). In this regard GLP-1RAs
exhibit potent metabolic effects, however they might also affect
other of the proposed targets. In the following paragraphs, we
will present the potential mechanisms of action of GLP-1RAs in
NAFLD provided by studies in humans (Figure 3).
Metabolic Effects
Bodyweight reduction
GLP-1 has a documented dose-dependent effect on satiety,
through central mechanisms in the hypothalamus and brainstem.
Accordingly, a reduced caloric intake has been observed in lean
and obese individuals and in patients with T2D after exogenously
administered GLP-1 during ad libitummeals. In addition, weight
loss is a consistent finding in clinical trials investigating GLP-
1RAs (27).
Reduction of hepatic and adipose tissue insulin resistance
An improved insulin sensitivity is expected after chronic
treatment with GLP-RAs mainly due to marked bodyweight
reductions. However, this effect might be independent of
changes in visceral fat accumulation since previous studies have
demonstrated that the hepatic glucose production is decreased in
healthy individuals following acute administration of both native
GLP-1 (43) and the GLP-1RA exenatide (44). Furthermore, in
patients with NASH, GLP-1 decreases de novo lipogenesis and
reduces levels of lipolysis-induced FFA and triglyceride-derived
toxic metabolites (45). Whether these actions could be partly
mediated through hepatic GLP-1R signaling remains uncertain,
as the presence of GLP-1Rs in the liver has not been confirmed
(46–48).
Insulinotropic effect
As alluded above, patients with NAFLD, in whole its spectrum
including cirrhotic individuals, show a reduced incretin effect.
Whether the insulinotropic action of GLP-1RAs, overcoming the
reduced incretin effect, might ameliorate NAFLD is however still
uncertain.
Inflammation and Oxidative Stress
The impact of GLP-1RAs on hepatic lipotoxicity has been
extensively explored in cellular and animal models, whereas few
clinical studies have been conducted (49). In NAFLD patients, the
increase in serum concentrations of total adiponectin following
GLP-1RAs treatment may be consistent with a restoration of
a dysfunctional adipose tissue (50). Liraglutide also decreases
fasting serum leptin resulting in a significant reduction in
the leptin-to-adiponectin ratio (45). In turn, adiponectin can
ameliorate NAFLD-associated liver abnormalities by regulating
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FIGURE 3 | Potential targets of GLP-1 receptor agonists in the treatment of NAFLD include: (A) a decrease in caloric intake through central regulation of satiety, (B) a
reduction of hepatic and adipose tissue insulin resistance due to decrease in body weight, (a direct effect may not be excluded, dashed lines) (C) a modified intestinal
lipoprotein metabolism, (D) a resolution of dysfunctional adipose tissue and (E) an enhancement of insulin release.
the oxidation of hepatic fatty acid and the activity of acetyl-CoA
carboxylase and fatty acid synthase, two key enzymes involved in
fatty acid synthesis (51).
Gut-Liver Axis
Lipoproteins production by the liver and by the intestine is
subject to a variety of hormonal and nutritional modulators and
is deranged in T2D as well as in insulin resistant states including
NAFLD (52). As carefully reviewed by Xiao et al. numerous
studies have demonstrated that GLP-1RAs may ameliorate
postprandial lipidemia during meal tests by multiple pathways
including decreased absorption of dietary fats as consequence
of reduced gut motility and direct inhibition of chylomicron
synthesis and secretion (53).
GLP-1RAs and Clinical Trials in NAFLD
Lixisenatide
In a systematic meta-analysis including 12 randomized
controlled trials (RCTs) comparing lixisenatide to placebo
or active interventions in T2D, lixisenatide was reported to
normalize levels of alanine aminotransferase (ALT) in a greater
proportion of overweight and obese patients with T2D than
comparators (54). However, at present, no trial aimed at testing
the efficacy of lixisenatide in patients with NAFLD has been
conducted.
Exenatide
Almost all human studies with exenatide twice-daily evaluating
NAFLD-related endpoints involve patients with T2D. Several
case series (55, 56) and open-label trials (57–60) suggest
that the combination of a better glycemic control, improved
metabolic parameters and bodyweight reductions achieved
by exenatide treatment as monotherapy or as add-on
to standard therapies may lead to improvements in liver
biomarkers and hepatic fat reductions in patients with T2D.
However, whether exenatide is able to ameliorate histological
features of NAFLD/NASH has not been investigated by
RCTs.
Liraglutide
Liraglutide is the only GLP-1RA, which has been investigated
for the treatment of NAFLD. In the “Liraglutide Efficacy and
Action in Diabetes” (LEAD) programme (61), a total of 154
patients with T2D within the LEAD-2 trial participated in
a sub-study to assess liver fat content by the liver-to-spleen
attenuation ratio at a computer tomography (CT) scan. Such
ratio significantly increased from baseline after 26 weeks of
treatment with liraglutide 1.8 mg/day, indicating a reduction in
liver steatosis, whereas it was unchanged in patients treated with
lower doses of liraglutide, glimepiride or placebo. Liraglutide
was also associated with a reduction in mean ALT levels,
which, however, disappeared after correction for changes in
weight and HbA1c (62, 63). An open-label uncontrolled trial
including 27 patients with T2D and NAFLD treated with
liraglutide 0.9 mg/day for 24 weeks showed a trend toward
increases in liver-to-spleen attenuation ratio assessed by CT
scan and, more importantly, a significant improvement in
histological inflammatory scores in 10 subjects undergoing liver
biopsies after a prolonged treatment of 96 weeks (64). In
patients with poorly controlled T2D, 6 months of treatment
with liraglutide 1.2 mg/day significantly reduced liver fat content
as evaluated by 1H-magnetic resonance spectroscopy, an effect
mainly driven by bodyweight loss (65). The first RCT to
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investigate the effect of liraglutide in patients with NAFLD
was the LEAN study, in which 52 patients with NASH were
randomized to either 48 weeks of treatment with liraglutide
(1.8 mg/day) or placebo (66). In this study, 39% of the
patients treated with liraglutide achieved histologic resolution
of NASH as compared to 9% in the control group (p =
0.019). Furthermore, worsening of fibrosis was significantly
reduced with liraglutide compared to placebo. With respect
to the previously mentioned study, this proof-of concept
study has important methodological strengths residing in the
availability of baseline and post-treatment hepatic biopsies.
Interestingly, reductions in bodyweight and HbA1c were similar
in patients with improvements in liver histology (“responders”)
and those without (“non-responders”), suggesting that, beyond
bodyweight reduction and improvement in glucose control,
other mechanisms may be involved in the beneficial effects of
liraglutide. The effect of liraglutide in NAFLD has also been
compared to other antidiabetic drugs. In 87 patients with NAFLD
and T2D, 12-week treatment with liraglutide 1.8 mg/d resulted
in similar reductions in intra-hepatic fat as treatment with
metformin, whereas liraglutide was significantly more effective
than gliclazide. In this trial, no differences in bodyweight changes
or glucose control among treatments were observed (67). In
one study, 12-week treatment with insulin glargine vs liraglutide
(mean dose = 1.3 mg/day) showed similar glycemic control
and decrease of hepatic fat burden, although a reduction in
BMI was only observed in the liraglutide-treated patients (68).
Furthermore, in a 12-week RCT in which patients were either
assigned to liraglutide (1.8 mg/day), sitagliptin (100 mg/day)
or placebo, no difference in glycemic control or bodyweight
reductions were found, and both treatments failed to reduce
liver hepatic fat content compared to placebo (69). A recent
randomized study comparing structured lifestyle modification (a
cornerstone in the currently recommended treatment of NASH)
to liraglutide 3 mg/day without lifestyle modifications showed
similar reductions in ALT and liver stiffness with no difference
in bodyweight variations. This findings indicate that an additive
effect of lifestyle modifications and liraglutide 3 mg/day might
exist (70).
Semaglutide
An ongoing phase 2 trial (NCT02970942) is currently
investigating the efficacy and safety of three doses of
subcutaneous semaglutide once-daily versus placebo in subjects
with NASH. It will include 288 participants. As in the LEAN
study, the primary outcome is histologic resolution of NASH
without worsening of fibrosis after 72 weeks of treatment, while
secondary outcomes include improvement in liver fibrosis (≥1
stage) with no worsening of NASH, NAFLD activity score,
as well as multiple serum markers of fibrosis. Furthermore,
a RCT (NCT03357380) is currently comparing the change in
early stages of scar tissue as well as fat deposition in the liver,
as detected by magnetic resonance imaging scans, in patients
treated with semaglutide or placebo for 72 weeks.
An overview on the clinical trials investigating GLP-1RAs
treatment in NAFLD is presented in Table 1.
EMERGING GLP-1 AND GLUCAGON
RECEPTOR CO-AGONISTS
Multiple GLP-1R co-agonists are emerging for the treatment
of obesity and diabetes. These agents, comprising GLP-1
combined molecules with glucagon or other hormones, have
been investigated in preclinical studies for NAFLD treatment.
Combination therapy and hybrid molecules that act through
multiple receptors appear to maximize the beneficial outcomes,
without increasing side effects of the single molecules. GLP-1
and glucagon display similar amino acid N-terminal sequences
and bind to structurally related receptors, facilitating the
development of single-molecule GLP-1R/GCGR co-agonists.
In general, GLP-1 and glucagon are believed to antagonize
their respective effects on glucose homeostasis. Whereas GLP-
1 decreases plasma glucose levels by exerting insulinotropic
effects, glucagon stimulates hyperglycemia by enhancing hepatic
glucose output. However, novel dual receptor agonists have
been developed for the treatment of obesity and T2D
under the concept that GLP-1 restrains the hyperglycemic
action of glucagon, while allowing it to exert its beneficial
actions on bodyweight, food intake, lipid metabolism and
thermogenesis (71).
One month-therapy with a pegylated GLP-1R/GCGR
dual agonists in diet-induced obese (DIO) mice resulted in
bodyweight loss and improved glycemic control. These effects
were coupled to an amelioration in lipid metabolism and hepatic
steatosis, which markedly exceeded the effect of single GLP-1RA
treatment (72). In 2016, another balanced dual receptor agonist
demonstrated pronounced effect on bodyweight and glucose
control, together with reducing hepatic fat content in rodents
and non-human primates (73). Recently, chronic exposure of a
GLP-1/glucagon dual analog conjugated with maleimide showed
beneficial effects on liver morphology in DIO mice (74).
Oxyntomodulin, a gut-derived peptide hormone, activates
both the GLP-1R and the GCGR, although, with reduced affinity
compared to GLP-1 and glucagon, respectively. Oxyntomodulin
has already shown to reduce food intake and bodyweight in
rodents and humans (75, 76). Interestingly, in a mouse model
of NASH, 2 weeks of treatment with a oxyntomodulin analog
also ameliorated the hepatic histopathological features of this
disease (77).
In addition to GLP-1R/GCGR dual agonists, a chimeric
peptide as dual GLP-1/GIP receptor agonists has been developed,
showing enhanced therapeutic potential for obesity and related
comorbidities. When compared to single agonists, unimolecular
dual incretin was more effective in correcting adiposity-induced
insulin resistance in animal models of obesity and diabetes; it also
improved liver function by reversing hepatic steatosis features in
histopathological specimens of DIOmice. In healthy and diabetic
subjects, the co-agonist displayed to improve glucose tolerance
and insulin secretion, although no data regarding bodyweight,
lipid metabolism, or liver function were reported (78). However,
preliminary studies in non-diabetic obese individuals showed
that simultaneous activation of GLP-1 and GIP receptors did not
potentiate GLP-1-mediated effects in lowering food intake and
appetite (79).
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This approach with dual agonists has been followed by
the development of monomeric triagonists, incorporating
residues from GLP-1, glucagon and GIP. In high-fat diet fed
mice, treatment with the triagonist dose-dependently improved
steatohepatitis and reduced levels of ALT, underpinning the
potential for this compound to treat liver disease (80).
While multi-agonism with incretin hormones and glucagon
has demonstrated great therapeutic potential, the conceptual
approach of polypharmacology has also been extended to other
hormone combinations. In pre-clinical studies, GLP-1 mediated
delivery of estrogen or dexamethasone has proven beneficial
effects on glucose tolerance, bodyweight control and systemic
inflammation (81). Interestingly, a conjugated glucagon and
thyroid hormone (T3) agonist has shown to reverse metabolic
syndrome related abnormalities (82). In a rodent model of
NASH, 3-week treatment with glucagon/T3 lowered ALT levels
and improved macroscopic and histological features of NASH,
including reversal of fibrosis (82).
CONCLUSION AND FUTURE
PERSPECTIVES
New knowledge about the pathophysiology of NAFLD has been
accumulating over the last decade, displaying the complexity
of the mechanisms involved in the development of this
condition. In addition to bodyweight loss through lifestyle
interventions, pharmacotherapies targeting adipose tissue,
the digestive system (gut-liver axis) and/or inflammation
are warranted. In this perspective, GLP-1RAs may act
through all of these different pathways. However, most
of the available GLP-1RAs have still not been thoroughly
investigated for the indication of NAFLD. Liraglutide treatment
has been shown to improve NASH histology and reduce
progression of fibrosis (66). Clinical trials investigating the
newly approved GLP-1RA semaglutide for the treatment
of NASH are currently ongoing. Another approach, which
seems promising for future treatment of NAFLD, is the
combination of GLP-1 and glucagon, since the latter may
potentiate incretin-mediated weight loss and increase lipid
utilization and FFA oxidation in the liver. With the additional
development of multiple new dual- and tri-agonist, GLP-
1 and glucagon-based poly-agonists in the treatment of
NAFLD represent an exciting novel pharmacological approach.
Whether the promising preclinical pharmacology will result in
successful clinical trials is a question that will be answered in
coming years.
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